- |||||||||| Tysabri (natalizumab) / Biogen, Tecfidera (dimethyl fumarate) / Biogen, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Impact of Switching from Natalizumab to a Moderate versus High Efficacy DMT in Clinical Practice at 24-Month Follow-Up () - Jan 21, 2020 - Abstract #AAN2020AAN_250; In our cohort, 48.6% switched to Mod DMT (dimethyl fumarate, n=130; fingolimod, n=140) vs. 23.4% who switched to HET (ocrelizumab, n=106; rituximab, n=17; alemtuzumab, n=7)... At 24 months, NTZ switchers to Mod DMT had lower cumulative probability of no disease activity by 24 months and were at higher risk of disability accumulation.
- |||||||||| Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
Lower Long-Term Disability with Early Start of High-Efficacy Therapies in Multiple Sclerosis () - Jan 21, 2020 - Abstract #AAN2020AAN_248; Those treated earlier had a more active disease course initially, which was then mitigated by their early aggressive management strategy. In patients with highly active MS, early exposure to high efficacy therapies is recommended.
- |||||||||| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1261;
Participants randomized to the BAT arm will be treated with either natalizumab, alemtuzumab, ocrelizumab, or rituximab... BEAT-MS will be a large scale prospective multi-center randomized clinical trial comparing AHSCT to contemporary high efficacy DMTs, with the goal of determining whether AHSCT is an appropriate treatment option for patients with highly active RMS for whom BAT would be prescribed in current clinical neurology practice.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Biomarker, Journal: Highly Aggressive Multiple Sclerosis. (Pubmed Central) - Dec 29, 2019 Selecting patients who are most appropriate for aggressive therapy involves considering risk factors for poor outcomes, early recognition of treatment failure, balancing treatment efficacy and side effects, and sharing the decision with patients to assist them in making optimal treatment choices. Vigilance for signs of treatment failure and early switching to more aggressive therapy are important components in optimal care.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Rituxan (rituximab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
Journal: Pregnancy and Family Planning in Multiple Sclerosis. (Pubmed Central) - Dec 29, 2019 Clinicians should avoid prescribing medications with known teratogenic potential (teriflunomide, fingolimod), known risk of severe rebound relapses (fingolimod, natalizumab), or unclear but plausible risks (dimethyl fumarate, alemtuzumab) to women of childbearing age who desire pregnancy or are not on reliable birth control. If a treatment needs to be resumed during breast-feeding, clinicians should opt for glatiramer acetate, interferon beta, natalizumab, or rituximab/ocrelizumab, as biologically plausible risks to the infant are exceedingly low.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes. (Pubmed Central) - Dec 23, 2019 Treatment choices for pediatric MS include many disease-modifying therapies (DMT) that are currently being used for adult MS and these are interferon-β 1a/1b (IFN-β1a/1b), glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, etc. However, most of these have not gone through complete testing in randomized, placebo-controlled clinical trials for pediatric MS and are being prescribed off-label by clinicians. As these studies are progressing, it is important to address if these approaches of treating pediatric MS patients have any long-term impact on patients, in particular, physical, cognitive, developmental and social outcomes of the children.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Journal: Alemtuzumab as Treatment for Multiple Sclerosis. (Pubmed Central) - Dec 21, 2019 Homeostatic proliferation of residual T cells after alemtuzumab-induced lymphopenia is probably responsible for its most common side effects: secondary autoimmunity 1 or 2 years after the last infusion of alemtuzumab affecting the thyroid gland (30% of patients), platelets (1%), or renal glomeruli (0.1%). With the prerequisite of patient and physician adherence to a prolonged safety-monitoring protocol, alemtuzumab offers durable high efficacy from infrequent dosing.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Journal: New Warning for the Multiple Sclerosis Drug Alemtuzumab. (Pubmed Central) - Dec 20, 2019 With the prerequisite of patient and physician adherence to a prolonged safety-monitoring protocol, alemtuzumab offers durable high efficacy from infrequent dosing. No abstract available
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Preclinical, Journal: Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model. (Pubmed Central) - Dec 2, 2019 The murine anti-CD52 antibody, an equivalent of the humanized antibody alemtuzumab, which is successfully used in the treatment of multiple sclerosis, was used to explore a potential neuroprotective effect driven by immune cell derived brain-derived neurotrophic factor (BDNF)...Neither therapeutic nor preventive application of the murine anti-CD52 antibody in an animal model of multiple sclerosis, the MOG EAE, revealed a beneficial contribution of immune cell derived BDNF to the disease outcome. Furthermore, preventive application of the murine anti-CD52 antibody worsened the clinical EAE disease course and could only be overcome by a prolonged recovery phase after treatment and before disease induction.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
Data-mining for Predicting Therapeutic Response in MS (Grand Ballroom, Convention Center) - Dec 1, 2019 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_25; The age at treatment initiation, together with dichotomizationof MS drugs into high- (ocrelizumab, mitoxantrone, alemtuzumab, daclizumab andnatalizumab) and low-efficacy (fingolimod, dimethyl fumarate, interferon-betapreparations, teriflunamide and glatiramer acetate) based on the age-adjustedlinear regression model residuals explained 68% of variance of inhibition ofdisability progression (R2 = 0.6757, p = 6.39 e-09)...Patients older than54 years may still benefit from current drugs if they experience MS relapses orhave contrast-enhancing lesions on brain/spinal cord MRI. However, therisk/benefit ratio of treating elderly MS patients without evidence of lesionalactivity with current MS drugs may be decidedly unfavorable.
- |||||||||| Journal: Cladribine (Mavenclad) for multiple sclerosis. (Pubmed Central) - Nov 13, 2019
Anti-CD52-based treatment, prior exposure to MS drugs, and on-treatment immune impairment are significant predictive factors of infection and their evaluation could help clinicians to stratify a patient's risk of infection. No abstract available
- |||||||||| prednisolone / Generic mfg., Lemtrada (alemtuzumab) / Sanofi
Antibody-Associated Autoimmune Disease (AAD) in Children with Cancer in Immune Recovery Phase Following Cessation of Chemotherapy (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1856; Prednisolone was administered in 3 patients (AIHA and ITP) to treat AAD...It was reported that IRS was also observed in HIV-negative patients who were administered alemtuzumab, and in those who received stem cell transplantation...We also speculate that AAD mimic autoimmune cytopenia such as ITP, AIHA, and autoimmune neutropenia in infancy because the diseases are caused by autoantibodies, occurring in immune-naive age, and they naturally recover in most cases although some patients need immunosuppressive treatment. Further studies are needed to clarify the pathogenesis of AAD in children.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Journal: Sarcoidosis following alemtuzumab treatment for multiple sclerosis. (Pubmed Central) - Oct 18, 2019 In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
|